Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
Research output: Contribution to journal › Journal article › Research › peer-review
Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.
| Original language | English |
|---|---|
| Journal | Clinical Epidemiology |
| Volume | 2 |
| Pages (from-to) | 145-51 |
| Number of pages | 7 |
| Publication status | Published - 1 Jan 2010 |
ID: 34052160